Patient & Visitor Alert: Because flu cases are on the rise, starting February 24, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities throughout Carolinas HealthCare System. Learn more.
This is a study for treatment-naïve HIV patients. This study is comparing the safety and efficacy of a new drug combination (GS-9883/FTC/TAF) to Dolutegravir + FTC/TAF. The trial is expected to last 2 years. The study sponsor will cover all cost related to the study including office visits, labs and medications.
Who may be Eligible
Patients may be eligible if they meet the following: Adults (18 years or older); HIV positive with no history of therapy; Normal maintenance labs and EKG; Agree to not become pregnant or father a child during the study; Agree to birth control methods as outlined by the study protocol; have no new infections in the past month that required hospitalization or IV therapy; No history of cancer in the past 5 years; New acute hepatitis B is an exclusion; Active tuberculosis is an exclusion.